<DOC>
	<DOCNO>NCT00000981</DOCNO>
	<brief_summary>To find oral dos FIAC ( pyrimidine nucleoside analog ) effective treat cytomegalovirus ( CMV ) viremia HIV-infected immunocompromised patient ; determine tolerance safety FIAC patient population ; determine pharmacokinetics follow multiple dos FIAC . ( An example another nucleoside analog effective retrovirus HIV zidovudine ( AZT ) . ) CMV infection medically significant opportunistic disease patient HIV-related infection . The purine nucleoside ganciclovir use treat AIDS patient CMV disease . Although ganciclovir useful treat CMV disease , treatment frequently complicate hematologic ( blood ) toxicity . Also , treatment difficult require daily intravenous dose . Test tube study show FIAC primary breakdown product FIAU highly specifically active several virus include CMV . A single-dose , pharmacokinetic ( blood level ) study show FIAC , take orally , readily absorb bloodstream , convert FIAU .</brief_summary>
	<brief_title>The Safety Effectiveness FIAC Treatment Cytomegalovirus ( CMV ) Patients With AIDS</brief_title>
	<detailed_description>CMV infection medically significant opportunistic disease patient HIV-related infection . The purine nucleoside ganciclovir use treat AIDS patient CMV disease . Although ganciclovir useful treat CMV disease , treatment frequently complicate hematologic ( blood ) toxicity . Also , treatment difficult require daily intravenous dose . Test tube study show FIAC primary breakdown product FIAU highly specifically active several virus include CMV . A single-dose , pharmacokinetic ( blood level ) study show FIAC , take orally , readily absorb bloodstream , convert FIAU . Patients treat outpatient general health permit . This continue 90 day failure basis efficacy , tolerance , toxicity . The dose escalation group patient use formula n + 0.7n . Entry new patient next high dose base result antiviral , tolerance , safety data prior cohort receive least 14 day therapy . Consecutively qualify patient enrol dose group base either disease severity expect tolerance . Although formally randomize due sequential nature study serious medical condition patient , every attempt avoid bias assign patient dose make . Patients advise avoid heavy exercise within 24 hour laboratory test .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Fiacitabine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Pentamidine aerosol prophylaxis recurrent Pneumocystis carinii pneumonia ( PCP ) patient currently receive treatment . Prior Medication : Allowed : Zidovudine ( AZT ) patient take drug &gt; 6 week dose = &lt; 600 mg/day , &lt; 10 percent decrease hematocrit , neutrophil , platelet last 30 day . Those AZT must &gt; 1 month . Patients must : Have document cytomegalovirus ( CMV ) viremia viruria . Have diagnosis HIV infection ELISA Western blot . Be able participate outpatient . Be ambulatory . Grade 0 1 AIDS Clinical Trial Group toxicity grade specify laboratory test . Be competent sign inform consent . Be able cooperate treatment plan evaluation schedule . NOTE : The screening test must initiate complete within 4 week prior first dose FIAC . Concomitant diseases allow : Stable mucocutaneous Kaposi 's sarcoma . Superficial uncomplicated infection thrush . Exclusion Criteria Coexisting Condition : Patients follow exclude : HIV waste syndrome ( involuntary weight loss &gt; 10 percent baseline body weight and/or chronic diarrhea weakness document fever least 30 day ) . Clinical xray evidence bronchitis , pneumonitis , pulmonary edema , effusion , suspect active tuberculosis . Any unstable medical condition include serious cardiovascular , infectious , oncologic , renal , hepatic condition . Cytomegalovirus end organ disease . Kaposi 's sarcoma require chemotherapy . Systemic fungal infection require amphotericin therapy . Diagnosis idiopathic thrombocytopenic purpura ( persistent platelet count &lt; 100000 platelets/mm3 = &gt; 3 month ) . Patients follow exclude : HIV waste syndrome . Clinical xray evidence bronchitis , pneumonitis , pulmonary edema , effusion , suspect active tuberculosis . Any unstable medical condition include serious cardiovascular , infectious , oncologic , renal , hepatic condition . Cytomegalovirus ( CMV ) end organ disease e.g. , retinitis , hepatitis , gastroenteritis . Prior Medication : Excluded within 4 week study entry : Zidovudine ( AZT ) . Acyclovir . Ganciclovir ( DHPG ) . Foscarnet . Interferon . Other drug putative anticytomegaloviral activity . Any immunostimulating drug specifically allow .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Pyrimidine Nucleosides</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>fiacitabine</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>